Assessing the impact of the early COVID-19 era on antibiotic-resistant threats in inpatient settings: A mixed Poisson regression approach

Am J Infect Control. 2023 Oct;51(10):1089-1094. doi: 10.1016/j.ajic.2023.04.159. Epub 2023 Apr 19.

Abstract

Background: During the COVID-19 pandemic, increased antibiotic prescribing and infection prevention challenges coincided with antibiotic-resistant (AR) infection increases. Clostridioides difficile (C difficile) and methicillin-resistant Staphylococcus aureus (MRSA) are serious, costly AR threats. Health inequities in pandemic-era AR infections are not well-characterized.

Methods: North Carolina statewide inpatient admissions were used to determine monthly admission rates and admission rate ratios (RRs) for C difficile and MRSA infections comparing 2017-2019 (prepandemic) to 2020 (pandemic exposure) using mixed-model Poisson regression adjusted for age, sex, comorbidities, and COVID-19. We assessed effect measure modification by admissions... community-level income, county rurality, and race and ethnicity. Mean total costs by infection type were compared.

Results: With pandemic exposure, C difficile (adjusted RR.ß=.ß0.90 [95% confidence interval [CI] 0.86, 0.94]) and MRSA pneumonia (adjusted RR.ß=.ß0.97 [95% CI 0.91, 1.05]) decreased, while MRSA septicemia (adjusted RR.ß=.ß1.13 [95% CI 1.07, 1.19]) increased. Effect measure modification was not detected. C difficile or MRSA coinfection nearly doubled mean costs among COVID-19 admissions.

Conclusions: Despite decreases in C difficile and most MRSA infections, the early COVID-19 pandemic period saw continued increases in MRSA septicemia admissions in North Carolina. Equitable interventions to curb increases and reduce health care costs should be developed.

Keywords: Admission rates; Clostridioides difficile; Health care cost; Health disparities; Methicillin-resistant Staphylococcus aureus.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • COVID-19* / epidemiology
  • Humans
  • Inpatients
  • Methicillin-Resistant Staphylococcus aureus*
  • Pandemics
  • Sepsis* / drug therapy
  • Staphylococcal Infections* / prevention & control

Substances

  • Anti-Bacterial Agents